Cargando…
11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis
11β-Hydroxysteroid dehydrogenase type-1 (11β-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11β-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11β-HSD1 deficiency on...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Federation of American Societies for Experimental Biology
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606528/ https://www.ncbi.nlm.nih.gov/pubmed/23303209 http://dx.doi.org/10.1096/fj.12-219105 |
_version_ | 1782264027580203008 |
---|---|
author | Kipari, Tiina Hadoke, Patrick W. F. Iqbal, Javaid Man, Tak-Yung Miller, Eileen Coutinho, Agnes E. Zhang, Zhenguang Sullivan, Katie M. Mitic, Tijana Livingstone, Dawn E. W. Schrecker, Christopher Samuel, Kay White, Christopher I. Bouhlel, M. Amine Chinetti-Gbaguidi, Giulia Staels, Bart Andrew, Ruth Walker, Brian R. Savill, John S. Chapman, Karen E. Seckl, Jonathan R. |
author_facet | Kipari, Tiina Hadoke, Patrick W. F. Iqbal, Javaid Man, Tak-Yung Miller, Eileen Coutinho, Agnes E. Zhang, Zhenguang Sullivan, Katie M. Mitic, Tijana Livingstone, Dawn E. W. Schrecker, Christopher Samuel, Kay White, Christopher I. Bouhlel, M. Amine Chinetti-Gbaguidi, Giulia Staels, Bart Andrew, Ruth Walker, Brian R. Savill, John S. Chapman, Karen E. Seckl, Jonathan R. |
author_sort | Kipari, Tiina |
collection | PubMed |
description | 11β-Hydroxysteroid dehydrogenase type-1 (11β-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11β-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11β-HSD1 deficiency on atherosclerosis and its inflammation, atherosclerosis-prone apolipoprotein E-knockout (ApoE-KO) mice were treated with a selective 11β-HSD1 inhibitor or crossed with 11β-HSD1-KO mice to generate double knockouts (DKOs) and challenged with an atherogenic Western diet. 11β-HSD1 inhibition or deficiency attenuated atherosclerosis (74–76%) without deleterious effects on plaque structure. This occurred without affecting plasma lipids or glucose, suggesting independence from classical metabolic risk factors. KO plaques were not more inflamed and indeed had 36% less T-cell infiltration, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower lesional vascular cell adhesion molecule-1 (VCAM-1). Bone marrow (BM) cells are key to the atheroprotection, since transplantation of DKO BM to irradiated ApoE-KO mice reduced atherosclerosis by 51%. 11β-HSD1-null macrophages show 76% enhanced cholesterol ester export. Thus, 11β-HSD1 deficiency reduces atherosclerosis without exaggerated lesional inflammation independent of metabolic risk factors. Selective 11β-HSD1 inhibitors promise novel antiatherosclerosis effects over and above their benefits for metabolic risk factors via effects on BM cells, plausibly macrophages.—Kipari, T., Hadoke, P. W. F., Iqbal, J., Man, T. Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C., Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R., Savill, J. S., Chapman, K. E., Seckl, J. R. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. |
format | Online Article Text |
id | pubmed-3606528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Federation of American Societies for Experimental Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-36065282013-04-03 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis Kipari, Tiina Hadoke, Patrick W. F. Iqbal, Javaid Man, Tak-Yung Miller, Eileen Coutinho, Agnes E. Zhang, Zhenguang Sullivan, Katie M. Mitic, Tijana Livingstone, Dawn E. W. Schrecker, Christopher Samuel, Kay White, Christopher I. Bouhlel, M. Amine Chinetti-Gbaguidi, Giulia Staels, Bart Andrew, Ruth Walker, Brian R. Savill, John S. Chapman, Karen E. Seckl, Jonathan R. FASEB J Research Communications 11β-Hydroxysteroid dehydrogenase type-1 (11β-HSD1) converts inert cortisone into active cortisol, amplifying intracellular glucocorticoid action. 11β-HSD1 deficiency improves cardiovascular risk factors in obesity but exacerbates acute inflammation. To determine the effects of 11β-HSD1 deficiency on atherosclerosis and its inflammation, atherosclerosis-prone apolipoprotein E-knockout (ApoE-KO) mice were treated with a selective 11β-HSD1 inhibitor or crossed with 11β-HSD1-KO mice to generate double knockouts (DKOs) and challenged with an atherogenic Western diet. 11β-HSD1 inhibition or deficiency attenuated atherosclerosis (74–76%) without deleterious effects on plaque structure. This occurred without affecting plasma lipids or glucose, suggesting independence from classical metabolic risk factors. KO plaques were not more inflamed and indeed had 36% less T-cell infiltration, associated with 38% reduced circulating monocyte chemoattractant protein-1 (MCP-1) and 36% lower lesional vascular cell adhesion molecule-1 (VCAM-1). Bone marrow (BM) cells are key to the atheroprotection, since transplantation of DKO BM to irradiated ApoE-KO mice reduced atherosclerosis by 51%. 11β-HSD1-null macrophages show 76% enhanced cholesterol ester export. Thus, 11β-HSD1 deficiency reduces atherosclerosis without exaggerated lesional inflammation independent of metabolic risk factors. Selective 11β-HSD1 inhibitors promise novel antiatherosclerosis effects over and above their benefits for metabolic risk factors via effects on BM cells, plausibly macrophages.—Kipari, T., Hadoke, P. W. F., Iqbal, J., Man, T. Y., Miller, E., Coutinho, A. E., Zhang, Z., Sullivan, K. M., Mitic, T., Livingstone, D. E. W., Schrecker, C., Samuel, K., White, C. I., Bouhlel, M. A., Chinetti-Gbaguidi, G., Staels, B., Andrew, R., Walker, B. R., Savill, J. S., Chapman, K. E., Seckl, J. R. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis. Federation of American Societies for Experimental Biology 2013-04 /pmc/articles/PMC3606528/ /pubmed/23303209 http://dx.doi.org/10.1096/fj.12-219105 Text en © FASEB This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Communications Kipari, Tiina Hadoke, Patrick W. F. Iqbal, Javaid Man, Tak-Yung Miller, Eileen Coutinho, Agnes E. Zhang, Zhenguang Sullivan, Katie M. Mitic, Tijana Livingstone, Dawn E. W. Schrecker, Christopher Samuel, Kay White, Christopher I. Bouhlel, M. Amine Chinetti-Gbaguidi, Giulia Staels, Bart Andrew, Ruth Walker, Brian R. Savill, John S. Chapman, Karen E. Seckl, Jonathan R. 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title_full | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title_fullStr | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title_full_unstemmed | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title_short | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
title_sort | 11β-hydroxysteroid dehydrogenase type 1 deficiency in bone marrow-derived cells reduces atherosclerosis |
topic | Research Communications |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3606528/ https://www.ncbi.nlm.nih.gov/pubmed/23303209 http://dx.doi.org/10.1096/fj.12-219105 |
work_keys_str_mv | AT kiparitiina 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT hadokepatrickwf 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT iqbaljavaid 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT mantakyung 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT millereileen 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT coutinhoagnese 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT zhangzhenguang 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT sullivankatiem 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT mitictijana 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT livingstonedawnew 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT schreckerchristopher 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT samuelkay 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT whitechristopheri 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT bouhlelmamine 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT chinettigbaguidigiulia 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT staelsbart 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT andrewruth 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT walkerbrianr 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT savilljohns 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT chapmankarene 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis AT seckljonathanr 11bhydroxysteroiddehydrogenasetype1deficiencyinbonemarrowderivedcellsreducesatherosclerosis |